Abstract: The present invention relates to a series of novel phenylaminopyridine derivatives and a use thereof for inhibiting capsid assembly and for preventing or treating virus infectious diseases thereby.

Abstract: The present invention relates to an anti-hepatitis B virus (HBV) composition containing ciclopirox or a pharmaceutically acceptable salt thereof; a pharmaceutical composition for preventing or treating an HBV-induced disease, which contains ciclopirox or a pharmaceutically acceptable salt thereof; a method for treating an HBV-induced disease, which includes a step of administering the pharmaceutical composition to a subject; and a health functional food composition for preventing or improving an HBV-induced disease, which contains ciclopirox or a physiologically acceptable salt thereof. The present invention has newly elucidated the HBV-inhibiting effect of ciclopirox, and overcame the problem of the existing drugs that cccDNA cannot be removed by monotherapy. In addition, the present invention provides a therapeutic agent capable of effectively inhibiting HBV by inhibiting core assembly during the life cycle of the virus.

Abstract: The present application relates to a pharmaceutical composition containing compound 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4-3H)-quinazolinone, and a pharmaceutically acceptable salt thereof for preventing and treating liver cancer, and the composition of the present application inhibits ROS-PI3K-AKT-TERT signal transduction, and thus can be favorably used in the treatment of a liver cell cancer, in which a protein involved in the signal transduction is overexpressed, especially, advanced liver cell cancer.

Abstract: The present application relates to a pharmaceutical composition containing compound 5-fluoro-3-phenyl-2-[(15)-1-(7H-purin-6-ylamino)propyl]-4-3H)-quinazolinone, and a pharmaceutically acceptable salt thereof for preventing and treating liver cancer, and the composition of the present application inhibits ROS-PI3K-AKT-TERT signal transduction, and thus can be favorably used in the treatment of a liver cell cancer, in which a protein involved in the signal transduction is overexpressed, especially, advanced liver cell cancer.

Abstract: Provided is a method of purifying monosilane. More particularly, the method includes removing impurities from a crude material containing monosilane and ethylene by fractional distillation (operation 1), and removing ethylene and residual impurities by passing the crude material purified in operation 1 through activated carbon (operation 2). According to the method, high-purity monosilane may be more simply and effectively obtained without additional production of byproducts by selectively adsorbing ethylene, which is difficult to separate by fractional distillation, using an activated carbon.

Abstract: Provided is a method of purifying monosilane. More particularly, the method includes removing impurities from a crude material containing monosilane and ethylene by fractional distillation (operation 1), and removing ethylene and residual impurities by passing the crude material purified in operation 1 through activated carbon (operation 2). According to the method, high-purity monosilane may be more simply and effectively obtained without additional production of byproducts by selectively adsorbing ethylene, which is difficult to separate by fractional distillation, using an activated carbon.